TC BioPharm (TCB) has acquired more space within Maxim Office Park to expanding its operations.
Currently in a 5,005 sq ft suite on the ground floor of Maxin 1, the firm has taken further space on the ground floor and a full suite on the third floor, totalling approximately 11,300 sq ft and taking TCB’s capacity at Maxim to 16,300 sq ft.
TCB plans to use part of the additional space to increase its manufacturing capacity as it commences phase IIa/III treatment of patients with skin, kidney and lung cancer. The remaining space will be used to develop new products based on TCB’s innovative ‘ImmuniCAR’ cancer therapy platform.
Angela Scott, TCB’s chief operating officer, said: “This facility expansion will allow TCB to treat more cancer patients with our game-changing immunotherapies. The team at Maxim has done everything possible to facilitate our growth in Scotland.”
Craig Ritchie from Maxim Office Park commented: “TC BioPharm’s clean room, lab and administration facility at Maxim has become a Scottish hub for immuno-cell therapy research, benefitting cancer patients in the UK and Europe. We are very proud to have the biotechnology company as a tenant and to be able to accommodate its growing requirements as it continues its innovative and potentially life-saving work.”
Craig Ritchie added: “The upgraded M8 will have a major positive impact on businesses along the motorway corridor and beyond, improving the road network throughout central Scotland. This improved accessibility, along with our extensive public transport offering – the Park is serviced by over 130 buses a day – is making the decision to relocate to Maxim easy for businesses.”
Cushman & Wakefield and Ryden represented Maxim Office Park in the transaction.